Cargando…

Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment

5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase. 5-FU is one of the most widely used chemotherapeutic drugs, although it has severe side effects that may vary between patients. Pharmacoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Negrei, Carolina, Hudita, Ariana, Ginghina, Octav, Galateanu, Bianca, Voicu, Sorina Nicoleta, Stan, Miriana, Costache, Marieta, Fenga, Concettina, Drakoulis, Nikolaos, Tsatsakis, Aristidis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917556/
https://www.ncbi.nlm.nih.gov/pubmed/27445811
http://dx.doi.org/10.3389/fphar.2016.00172
_version_ 1782438958040350720
author Negrei, Carolina
Hudita, Ariana
Ginghina, Octav
Galateanu, Bianca
Voicu, Sorina Nicoleta
Stan, Miriana
Costache, Marieta
Fenga, Concettina
Drakoulis, Nikolaos
Tsatsakis, Aristidis M.
author_facet Negrei, Carolina
Hudita, Ariana
Ginghina, Octav
Galateanu, Bianca
Voicu, Sorina Nicoleta
Stan, Miriana
Costache, Marieta
Fenga, Concettina
Drakoulis, Nikolaos
Tsatsakis, Aristidis M.
author_sort Negrei, Carolina
collection PubMed
description 5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase. 5-FU is one of the most widely used chemotherapeutic drugs, although it has severe side effects that may vary between patients. Pharmacogenetic studies related to 5-FU have been traditionally focused on the rate-limiting catabolic enzyme, dihydropyrimidine dehydrogenase that breaks 80–85% of 5-FU into its inactive metabolite. Choosing the right dosing scheme and chemotherapy strategy for each individual patient remains challenging for personalized chemotherapy management. In the general effort toward reduction of colorectal cancer mortality, in vitro screening studies play a very important role. To accelerate translation research, increasing interest has been focused on using in vivo-like models such as three-dimensional spheroids. The development of higher throughput assays to quantify phenotypic changes in spheroids is an active research area. Consequently, in this study we used the microarray technology to reveal the HT-29 colorectal adenocarcinoma cells gene expression signature as response to 5-FU/OXP/FA treatment in a state of the art 3D culture system. We report here an increased reactive oxygen species production under treatment, correlated with a decrease in cell viability and proliferation potential. With respect to the HT-29 cells gene expression under the treatment with 5-FU/OXP/FA, we found 15.247 genes that were significantly differentially expressed (p < 0.05) with a fold change higher that two-fold. Among these, 7136 genes were upregulated and 8111 genes were downregulated under experimental conditions as compared to untreated cells. The most relevant and statistic significant (p < 0.01) pathways in the experiment are associated with the genes that displayed significant differential expression and are related to intracellular signaling, oxidative stress, apoptosis, and cancer.
format Online
Article
Text
id pubmed-4917556
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-49175562016-07-21 Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment Negrei, Carolina Hudita, Ariana Ginghina, Octav Galateanu, Bianca Voicu, Sorina Nicoleta Stan, Miriana Costache, Marieta Fenga, Concettina Drakoulis, Nikolaos Tsatsakis, Aristidis M. Front Pharmacol Pharmacology 5-FU cytotoxicity mechanism has been assigned both to the miss-incorporation of fluoronucleotides into RNA and DNA and to the inhibition of thymidylate synthase. 5-FU is one of the most widely used chemotherapeutic drugs, although it has severe side effects that may vary between patients. Pharmacogenetic studies related to 5-FU have been traditionally focused on the rate-limiting catabolic enzyme, dihydropyrimidine dehydrogenase that breaks 80–85% of 5-FU into its inactive metabolite. Choosing the right dosing scheme and chemotherapy strategy for each individual patient remains challenging for personalized chemotherapy management. In the general effort toward reduction of colorectal cancer mortality, in vitro screening studies play a very important role. To accelerate translation research, increasing interest has been focused on using in vivo-like models such as three-dimensional spheroids. The development of higher throughput assays to quantify phenotypic changes in spheroids is an active research area. Consequently, in this study we used the microarray technology to reveal the HT-29 colorectal adenocarcinoma cells gene expression signature as response to 5-FU/OXP/FA treatment in a state of the art 3D culture system. We report here an increased reactive oxygen species production under treatment, correlated with a decrease in cell viability and proliferation potential. With respect to the HT-29 cells gene expression under the treatment with 5-FU/OXP/FA, we found 15.247 genes that were significantly differentially expressed (p < 0.05) with a fold change higher that two-fold. Among these, 7136 genes were upregulated and 8111 genes were downregulated under experimental conditions as compared to untreated cells. The most relevant and statistic significant (p < 0.01) pathways in the experiment are associated with the genes that displayed significant differential expression and are related to intracellular signaling, oxidative stress, apoptosis, and cancer. Frontiers Media S.A. 2016-06-23 /pmc/articles/PMC4917556/ /pubmed/27445811 http://dx.doi.org/10.3389/fphar.2016.00172 Text en Copyright © 2016 Negrei, Hudita, Ginghina, Galateanu, Voicu, Stan, Costache, Fenga, Drakoulis and Tsatsakis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Negrei, Carolina
Hudita, Ariana
Ginghina, Octav
Galateanu, Bianca
Voicu, Sorina Nicoleta
Stan, Miriana
Costache, Marieta
Fenga, Concettina
Drakoulis, Nikolaos
Tsatsakis, Aristidis M.
Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
title Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
title_full Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
title_fullStr Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
title_full_unstemmed Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
title_short Colon Cancer Cells Gene Expression Signature As Response to 5- Fluorouracil, Oxaliplatin, and Folinic Acid Treatment
title_sort colon cancer cells gene expression signature as response to 5- fluorouracil, oxaliplatin, and folinic acid treatment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917556/
https://www.ncbi.nlm.nih.gov/pubmed/27445811
http://dx.doi.org/10.3389/fphar.2016.00172
work_keys_str_mv AT negreicarolina coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT huditaariana coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT ginghinaoctav coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT galateanubianca coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT voicusorinanicoleta coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT stanmiriana coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT costachemarieta coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT fengaconcettina coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT drakoulisnikolaos coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment
AT tsatsakisaristidism coloncancercellsgeneexpressionsignatureasresponseto5fluorouraciloxaliplatinandfolinicacidtreatment